3-(2,2,2-trimethylhydrazine)propionate has been researched along with Heart Disease, Ischemic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ball, V; Curtis, MK; Hauton, D; Heather, LC; Holzner, L; Savic, D; Timm, KN; Tyler, DJ | 1 |
| Fabritskaya, SV; Shilina, NN; Statsenko, S; Turkin, SV | 1 |
| Gorbach, TV; Kukes, VG; Romashchenko, OV; Rumbesht, VV; Zhernakova, NI | 1 |
| Biziaeva, EA; Karpova, ÉS; Kotel'nikova, EV; Liamina, NP; Lipchanskaia, TP; Senchikhin, VN | 1 |
| Karpov, ES; Lyamina, NP; Razborov, IB | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L | 1 |
| Daĭia, D; Dambrova, M; Kalvin'sh, I; Kir'ianova, O; Liepin'sh, E | 1 |
| Baumane, L; Boucher, JL; Dzintare, M; Kalvinsh, I; Kleschyov, AL; Meirena, D; Münzel, T; Sjakste, J; Sjakste, N; Sydow, K | 1 |
| Ivanova, MV; Liubimtseva, SA; Polonskaia, IaV; Ragino, IuI; Shabalin, AV | 1 |
| Kutuzova, AE; Nedoshivin, AO; Perepech, NB; Petrova, NN | 1 |
| Artiukh, VP; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
1 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Disease, Ischemic
| Article | Year |
|---|---|
[Biochemical mechanisms of mildronate action during ischemic stress].
Topics: Animals; Cardiovascular Agents; Carnitine; Clinical Trials as Topic; Humans; Methylhydrazines; Myocardial Ischemia; Myocardium; Oxidative Stress; Treatment Outcome | 2004 |
2 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Disease, Ischemic
| Article | Year |
|---|---|
[Cardioprotective capabilities of drug meldonium in secondary prevention after percutaneous coronary intervention in patients with documented myocardial ischemia].
Topics: Adaptation, Physiological; Administration, Intravenous; Cardiotonic Agents; Coronary Angiography; Dose-Response Relationship, Drug; Drug Monitoring; Exercise Test; Exercise Therapy; Female; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Treatment Outcome; Vascular Patency | 2014 |
[Effect of cytoprotection on the oxidative processes and endothelial function in elderly patients with ischemic heart disease].
Topics: Aged; Aged, 80 and over; Cytoprotection; Endothelium, Vascular; Female; Humans; Lipid Peroxides; Lipids; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Nitric Oxide; Oxidative Stress; Treatment Outcome | 2006 |
8 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Disease, Ischemic
| Article | Year |
|---|---|
Hyperpolarized magnetic resonance shows that the anti-ischemic drug meldonium leads to increased flux through pyruvate dehydrogenase in vivo resulting in improved post-ischemic function in the diabetic heart.
Topics: Animals; Diabetes Mellitus, Experimental; Glucose; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methylhydrazines; Myocardial Ischemia; Myocardium; Pyruvate Dehydrogenase Complex; Rats; Rats, Wistar; Streptozocin | 2021 |
[Efficacy of Short-Term Therapy With Meldonium in Patients With Chronic Heart Failure of Ischemic Etiology and Type 2 Diabetes Mellitus].
Topics: Aged; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 2017 |
[Efficiency of mildronate in rats of different age with experimental-induced myocardial ischemia].
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Age Factors; Animals; Cardiovascular Agents; Creatine Kinase; Decarboxylation; Energy Metabolism; Glycolysis; Isoenzymes; L-Lactate Dehydrogenase; Male; Methylhydrazines; Myocardial Ischemia; Myocytes, Cardiac; Pyruvates; Rats; Rats, Wistar | 2013 |
[Clinical and Economic Aspects of Meldonium as Part of Physical Rehabilitation Programs in Patients With Coronary Heart Disease After Percutaneous Coronary Interventions].
Topics: Cardiovascular Agents; Coronary Disease; Exercise Test; Exercise Tolerance; Female; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Treatment Outcome | 2016 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructosamine; Heart; Hyperalgesia; Hypoglycemic Agents; In Vitro Techniques; Lipids; Male; Methylhydrazines; Myocardial Ischemia; Pain Threshold; Rats; Rats, Wistar | 2009 |
Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate.
Topics: Animals; Aorta, Thoracic; Betaine; Carnitine; Ditiocarb; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Electron Spin Resonance Spectroscopy; Endothelium; Male; Methylhydrazines; Muscle, Smooth, Vascular; Myocardial Ischemia; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Vasodilation | 2004 |
[Effect of mildronate on life quality of patients with chronic heart failure].
Topics: Administration, Oral; Adult; Cardiovascular Agents; Chronic Disease; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Patient Satisfaction; Quality of Life; Stroke Volume; Treatment Outcome | 1999 |
[Erythrocyte functional activity in patients with heart failure and the possible means for its correction].
Topics: Adult; Aged; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Erythrocytes; Heart Failure; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 1992 |